Trigeminal neuralgia
Conditions
Sponsors
Noro Shusaku
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients aged 18 years or older at the time of informed consent. (2)Patients diagnosed with trigeminal neuralgia; 13.1.1.1 Classical trigeminal neuralgia and 13.1.1.3 Idiopathic trigeminal neuralgia, according to the International Classification of Headache Disorders 3rd edition (ICHD3) (3)Patients whose NRS pain score at the patient registration is 5 or higher. (4)Patients who are able to perform NRS self-assessment appropriately. (5)Patients who gave written informed consent based on their own free will after receiving adequate explanation and fully understanding the details of the explanation in participating in the study.
Exclusion criteria
Exclusion criteria: (1)Patients who are suspected to be increased intracranial pressure. (2)Patients who are complicated with epilepsy, serious mental or neuropsychiatric disorders (including dementia, Parkinson's disease, or schizophrenia) or consciousness disturbance. (3) Patients who are being treated for malignancy. However, those who do not interfere with daily life and have good general condition may be included in the study. (4)Patients with suspected herpes zoster or postherpetic neuralgia (trigeminal area) (5)Patients who have other severe pain that may affect the assessment of pain associated with trigeminal neuralgia. (6)Patients who have sinus bradycardia or advanced conduction disturbance. (7)Patients who have a history of hypersensitivity to hydantoin. (8)Patients who are receiving drugs that are contraindicated in the package insert for fosphenytoin. (9)Patients who have serious cardiac disease, respiratory disorder, or hepatic or renal dysfunction (10)Patients who received surgical treatment for the trigeminal neuralgia within 2 weeks of the study drug (11)Patients who received fosphenytoin, phenytoin, ethotoin and their combination drugs within 2 weeks of the study drug (12)Patients who participated in this study and recived the study drug (13)Patients who have participated in other clinical study(exclude observational studies) within 3 months of the date of the study drug administration. (14)Pregnant women, lactating women or patients of childbearing potential during the study period. (15)Other patients who are deemed inappropriate for participation in the study by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the NRS pain score from baseline at 120 minutes after the study drug administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1)Change in the NRS pain score from baseline at each assessment time point up to 120 minutes after the first maintenance dose. (2)Numbers of trigeminal neuralgia attacks from immediately after the study drug administration to immediately before the first maintenance dose. (3)Change in the NRS pain score from baseline at each assessment time point after the study drug administration. (4)Time to the first disappearance of the event (Time to event) during the period from immediately after the study drug administration to immediately before the first maintenance dose. (5)The proportion of responders defined as a 50% reduction in NRS pain score from baseline to 120 minutes after the study drug administration. (6)The improvement rate of patient impression scores at assessment time point of the day after the last dose. (7) Change in the SF-8 (24-hour version) score for QOL from baseline. | — |
Contacts
Public ContactShusaku Noro
Nakamura Memorial Hospital
Outcome results
None listed